Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001516551-24-000110
Filing Date
2024-11-07
Accepted
2024-11-07 16:10:16
Documents
68
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q skye-20240930.htm   iXBRL 10-Q 932911
2 EX-10.1 skyeex101bio-amendedandres.htm EX-10.1 170988
3 EX-31.1 skye-20240930xex311xsectio.htm EX-31.1 10504
4 EX-31.2 skye-20240930xex312xsectio.htm EX-31.2 11033
5 EX-32.1 skye-20240930xex321xsectio.htm EX-32.1 5085
6 EX-32.2 skye-20240930xex322xsectio.htm EX-32.2 5225
  Complete submission text file 0001516551-24-000110.txt   5741003

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT skye-20240930.xsd EX-101.SCH 46125
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT skye-20240930_cal.xml EX-101.CAL 68818
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT skye-20240930_def.xml EX-101.DEF 218263
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT skye-20240930_lab.xml EX-101.LAB 590497
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT skye-20240930_pre.xml EX-101.PRE 394580
70 EXTRACTED XBRL INSTANCE DOCUMENT skye-20240930_htm.xml XML 644452
Mailing Address 11250 EL CAMINO REAL, SUITE 100 SAN DIEGO CA 92130
Business Address 11250 EL CAMINO REAL, SUITE 100 SAN DIEGO CA 92130 (858) 410-0266
Skye Bioscience, Inc. (Filer) CIK: 0001516551 (see all company filings)

EIN.: 450692882 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-42009 | Film No.: 241435725
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)